Table 3 Efficacy and effectiveness data for pneumococcal vaccines
From: Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
| PCV13 | PPV23 | |||
|---|---|---|---|---|
| IPD | ||||
| Age Group | Efficacy | Serotype Coverage | Efficacy | Serotype Coverage |
| 18 - 39 | 93.9% [26]* | 67.9% | 74.0%*[9] | 83.3% |
| 40 - 49 | 75.4% | 78.5% | ||
| 50 - 59 | 63.4% | 78.9% | ||
| 60 - 69 | 63.9% | 83.6% | ||
| 70 - 79 | 71.4% | 78.3% | ||
| 80 - 89 | 74.8% | 84.5% | ||
| ≥ 90 | 76.2% | 90.5% | ||
| Inpatient CAP / Outpatient CAP (all cause) | ||||
| Age Group | Effectiveness | Effectiveness | ||
| All | 26.0%/6% [27, 28] | 0%/0% [6, 9, 19] | ||